BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 28, 2002
View Archived Issues
MedImmune Expects To Take FluMist Back To Panel This Year
An FDA advisory panel later this year is expected to vote on whether FluMist should enter the market as a nasal influenza vaccine for patients who are ages 19 months to 64 years old. (BioWorld Today)
Read More
NPS Prices $95.8M Offering From Shelf For Phase III Trials
Read More
Rats' Antennae-Like Whiskers Perform Mental Arithmetic, By Neuronal Spectral Mixing
Read More
Harvard Bioscience Completes Genomics Solutions Acquisition
Read More
Epimmune To Test Public Waters With $9.6M Offering
Read More
Other News To Note
Read More